Product Candidate

Fabomotizole: A Third-Generation Anxiolytic Drug

Fabomotizole (4-[2-[(6-ethoxy-1H-benzimidazol-2-yl)sulfanyl]ethyl]morpholine) is an anxiolytic drug that produces anxiolytic and neuroprotective effects without significantly sedative, hypnotic, or muscle relaxant properties.

The drug eliminates the manifestations of anxiety and stress and stabilizes the structure of corresponding receptors, restores the normal sensitivity of nerve cell receptors, and protects against further stress. The action of fabomotizole is through sigma-agonistic, melatonergic, indirect GABAergic, membrane-stabilizing, and weak MAO-A inhibitor activities.

Fabomotizole is not an agonist of benzodiazepine or barbiturate sites of GABA receptors. Thus, it does not have the classical drawbacks of those well-known classes of anxiolytics. The drug has no negative impact on the ability to drive vehicles and perform potentially dangerous activities requiring increased attention concentration and speed of psychomotor reactions.

Fabomotizole has few side effects. Allergic reactions are possible. Rarely a headache occurs, which usually resolves on its own and does not require discontinuation of the drug. A significant overdose can cause a sedative effect and increased drowsiness without manifestations of muscle relaxation.